SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing intense downward pressure and high volatility as investors weigh bearish downgrades from institutional analysts against rumors of a potential SpaceX IPO. The community remains deeply polarized, with many retail traders actively hunting for a bottom while others express frustration over the company's valuation, delivery timelines, and the broader shift in Elon Musk's focus toward other ventures.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing significant price action as investors react to the CMS finalizing a Medicare Advantage rate increase for 2027 that exceeded previous, more conservative projections. While many in the community view this as a potential bullish catalyst for a short squeeze and long-term sector stability, others remain cautious, debating whether this relief is sufficient to overcome ongoing regulatory headwinds and broader market volatility.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is currently trending following a massive, long-term partnership with Google to design next-generation custom AI silicon and networking components through 2031, alongside an expanded collaboration with Anthropic. Investors are closely monitoring the stock as it stabilizes near key support levels, with the community actively debating whether this infrastructure dominance justifies its valuation or if broader semiconductor sector rotation will drive further volatility.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum is experiencing extreme volatility and intense debate among traders as it aggressively tests all-time highs, with the community divided between those betting on continued AI infrastructure growth and those calling it a classic overextended bubble. Investors are closely watching its parabolic price action alongside other optical hardware plays, as high-conviction call buying and heavy institutional volume drive significant momentum in both directions.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending following the official announcement of a long-term partnership with Broadcom to develop custom AI silicon and networking components through 2031. Investors and community members are closely debating the potential for this infrastructure deal to secure Google's AI leadership while navigating broader concerns regarding sector rotation, regulatory antitrust pressures, and the recent negative outcomes of social media addiction lawsuits.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Seagate Technology is experiencing significant momentum and investor attention as analysts raise price targets, citing strong demand for high-capacity hard disk drives through 2028. The community is actively debating whether this represents a sustainable structural re-rating driven by long-term data center and AI infrastructure needs, or if it is a classic cyclical peak prone to volatility and eventual distribution.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is gaining momentum as investors pivot toward AI infrastructure following news of expanded compute deals with major tech giants and reports of imminent CPU price hikes. While some market participants express caution regarding geopolitical volatility and short-term price swings, the community remains actively focused on the company's long-term potential as a co-leader in the AI era with its upcoming MI400-series and 2nm architecture.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is capturing investor attention following an across-the-board subscription price hike aimed at funding an aggressive multi-billion dollar content strategy. The stock is exhibiting relative strength and active bullish sentiment, with market participants closely monitoring potential breakout levels above the hundred-dollar mark as institutional capital continues to rotate into the ticker.

NKN is building the largest blockchain for network sharing.

New Kind of Network

NKN is capturing significant investor attention as market participants look for low-cap momentum plays, with community discussion heavily focused on rumors of potential partnerships and speculative short-squeeze theories. While some users are actively accumulating on dips in anticipation of a technical breakout, others remain cautious, pointing to the coin's history of volatility and the risks associated with highly speculative, low-priced assets.

Royal Bank of Canada engages in the provision of banking and financial services. It operates through the following segments: Personal and Commercial Banking, Wealth Management, Insurance, Capital Markets, and Corporate Support. The Personal and Commercial Banking segment deals with a broad suite of financial products and services in both individual and business clients in Canada, the Caribbean, and the U.S. The Wealth Management segment offers a suite of wealth, investment, trust, banking, credit, and other advice-based solutions. It also offers other wealth management solutions to institutional and individual clients through its distribution channels and third-party distributors. The Insurance segment refers to a suite of advice and solutions for individual and business clients including life, health, wealth, property and casualty, travel, group benefits, annuities, and reinsurance. The Capital Markets segment is involved in the provision of advisory and origination, sales and trading, lending and financing and transaction banking to corporations, institutional clients, asset managers, private equity firms and governments globally. The Corporate Support segment consists of technology and operations services. The company was founded by J. W. Merkell, Edward Kenny, T. C. Kinnear, James B. Duffus, William Cunard, John Tobin, George P. Mitchell and Jeremiah Northup in 1864 and is headquartered in Toronto, Canada.

Royal Bank Of Canada

Royal Bank of Canada is seeing active discussion regarding a significant lawsuit filed by Quantum BioPharma, which accuses the bank and others of market manipulation and spoofing. Market participants are closely watching how this legal challenge impacts the bank's reputation, while others continue to debate the broader stability of Canadian financial institutions amidst shifting economic conditions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rocket Pharmaceuticals, Inc. $RCKT Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 73.6% during the third quarter, according to its most recent disclosure with the SEC...

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.

Bank of America Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Bank of America upped their target price on shares of Rocket Pharmaceuticals from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Monday...

<ul class="summary-bullets"><li>The company also said that the FDA granted the company a Rare Pediatric Disease Priority Review Voucher (PRV) following the approval.</li><li>Wedbush reiterated an ‘Outperform’ rating and $16 price target on Rocket Pharmaceuticals, saying the Kresladi approval is a "significant milestone" for the company.</li><li>LifeSci Capital added that it is impressive Rocket was able to usher Kresladi through a complex cell-based gene therapy approval.</li></ul>&nbsp;Shares of Rocket Pharmaceuticals Inc. (RCKT) dropped 22% on Friday after the company announced U.S. Food and Drug Administration's approval for its drug in the treatment of an inherited pediatric disorder, a sell-off that Wall Street dismissed as unjustified.Earlier on Friday, Rocket announced that the FDA has approved its gene therapy Kresladi for the treatment of certain pediatric patients with severe leukocyte adhesion deficiency-I, an ultra-rare, inherited pediatric immunodeficiency characterized by recurrent, severe infections.The company also said that the FDA granted the company a Rare Pediatric Disease Priority Review Voucher (PRV) following the approval. The voucher is designed to encourage the development of therapies for rare pediatric disease<h2 class="st-heading-2">Wall Street Weighs In</h2>Wedbush reiterated an ‘Outperform’ rating and $16 price target on Rocket Pharmaceuticals, saying the Kresladi approval is a "significant milestone" for the company, which the firm believes reflects management's strong execution. Payer coverage should not be an issue, and the priority review voucher will strengthen Rocket's balance sheet, the analyst told investors in a research note. The firm added that it does not see the negative stock price reaction as justified.LifeSci Capital analyst Patrick Dolezal also reiterated an ‘Outperform’ rating and $9 price target on Rocket Pharmaceuticals. The firm said the PRV could be a potentially meaningful source of non-dilutive capital that could net Rocket $100 million to $200 million. The firm added that it is impressive Rocket was able to usher Kresladi through a complex cell-based gene therapy approval and expects read-through to the company's cardiac gene-therapy pipeline.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around RCKT stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/RCKT">RCKT stock</a> has fallen 53% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-model-y-3-deliveries-critical-as-model-s-x-approach-retirement-says-analyst/cZ3HJsGRIm9">Watch Tesla Model Y/3 Q1 Delivery Numbers Closely — Analyst Warns As S/X Near End Of Production</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off

Earlier on Friday, Rocket announced that the FDA has approved its gene therapy Kresladi for the treatment of certain pediatric patients with an ultra-rare immune disorder.

Equity

Earlier on Friday, Rocket announced that the FDA has approved its gene therapy Kresladi for the treatment of certain pediatric patients with an ultra-rare immune disorder.


Chardan Capital Reiterates Buy Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

Chardan Capital restated a "buy" rating and issued a $11.00 target price on shares of Rocket Pharmaceuticals in a research note on Friday...

Promising Biotech Stocks To Add to Your Watchlist - March 27th

Danaher, Onconetix, Moderna, argenex, Vertex Pharmaceuticals, Abivax, and Rocket Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

Rocket Pharmaceuticals Wins FDA Accelerated Approval for KRESLADI Gene Therapy in Severe LAD-I Kids

Rocket Pharmaceuticals (NASDAQ:RCKT) said the U.S. Food and Drug Administration has granted accelerated approval to KRESLADI (RP-L201), a lentiviral vector-based gene therapy for pediatric patients with severe leukocyte adhesion deficiency type I (LAD-I). Company executives described the decision as...

AI, Biotech, and Biologics Drive Big Narratives

A new wave of healthcare innovation, powered by artificial intelligence, next-generation biologics, and shifting regulatory pathways, is colliding with market dynamics to create both breakthrough potential and high-volatility trading setups. $ARTL, $TGNT, $ADMA, $RCKT, $LTRN, $GCTK

Why Is Rocket Pharma Stock Soaring Friday?

Rocket Pharmaceuticals stock jumps after FDA nod for Kresladi in LAD-I; voucher sale may boost cash runway and support growth plans.read more...

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced...

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Current Price	$3.46
Prev Close	$3.55
Open	$3.48
Dividend Yield	0.00%
50-Day Moving Average	$4.02
Beta	1.17
Avg. Volume	5.11M
PE Ratio	-1.72

52-Week High	$8.26
52-Week Low	$2.19
Market Capitalization	$385.42M
EPS (Annual)	-$2.01
Price to Book	1.35
Revenue Per Employee	$0.00

RCKT
Rocket Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RCKT News

RCKTRocket Pharmaceuticals Inc